Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects
Status:
Completed
Trial end date:
2019-10-06
Target enrollment:
Participant gender:
Summary
QPX2015 (beta-lactam antibiotic) is being studied at higher than approved doses to combine
with a new beta-lactamase inhibitor to treat bacterial infections, including those due to
multi-drug resistant bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Qpex Biopharma, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority